Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Actelion Names Muller as CFO as Oakley Leaves Swiss Drugmaker

Don't Miss Out —
Follow us on:

Aug. 27 (Bloomberg) -- Actelion Ltd., the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, said Andre Muller will replace Chief Financial Officer Andrew Oakley, who is leaving the company.

Muller, 49, will start the position on Sept. 1, the Allschwil-based company said in a statement today. Oakley, 51, is leaving to “focus on opportunities outside Actelion,” the drugmaker said.

Muller is moving from Pierre Fabre SA, a maker of pharmaceuticals and cosmetics, where he held the same position. Oakley has been CFO of Actelion for 10 years.

Actelion raised its full-year profit forecast in July as second-quarter sales beat estimates and it cut spending. The improved outlook may renew takeover speculation, Andrew Weiss, an analyst at Bank Vontobel AG in Zurich, said at the time.

To contact the reporter on this story: Thomas Mulier in Geneva at tmulier@bloomberg.net

To contact the editor responsible for this story: David Risser at drisser@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.